COMMUNIQUÉS West-GlobeNewswire

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
30/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Bright Minds Biosciences to Present at Upcoming Conferences
30/10/2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the [...]
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
31/10/2025
Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patients LA JOLLA, Calif., Oct. 30, 2025 (GLOBE [...]
Nkarta to Participate in November Investor Conferences
30/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its [...]
‘Do I Qualify for Lung Cancer Screening?’: Understanding Your Path to Early Detection Could Save Your Life
30/10/2025
While other organized screening programs are well-established, organized lung cancer screening remains less familiar to many Canadians, yet it’s a crucial and accessible way to protect your health. Lung Health [...]
CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2025
30/10/2025
Communiqué de presse CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2025 DIJON, France – 30 octobre 2025 (20H00 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société [...]
GENFIT annonce son intention de procéder au retrait volontaire de la cotation de ses « American Depositary Shares » sur le Nasdaq Global Select Market
30/10/2025
La décision de GENFIT de retrait du Nasdaq traduit une volonté stratégique de simplifier sa structure organisationnelle et d'améliorer son efficacité opérationnelle Les actions de GENFIT restent cotées sur le marché [...]
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
30/10/2025
GENFIT’s decision to delist from Nasdaq reflects strategic intent to simplify corporate structure and improve operational efficiency GENFIT remains listed on the regulated market of Euronext Paris as its primary trading [...]
TME Pharma publie ses résultats semestriels et son rapport de mi-année
30/10/2025
TME Pharma publie ses résultats semestriels et son rapport de mi-année Berlin, Allemagne, 30 octobre 2025, 21h00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), Une société de biotechnologie en phase clinique, [...]
TME Pharma publishes its semi annual results and half-year report
30/10/2025
TME Pharma publishes its semi annual results and half-year report Berlin, Germany , October 30, 2025, 21.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in [...]
¬Nephros Schedules Third Quarter 2025 Financial Results Conference Call
30/10/2025
SOUTH ORANGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will [...]
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
30/10/2025
--Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study [...]
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
30/10/2025
Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA ® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to be between $270- [...]
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call
30/10/2025
RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third quarter 2025 financial [...]
Ligand to Participate in November Investor Conferences
30/10/2025
JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in [...]
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy
30/10/2025
-- Webcast event to begin at 8:00am ET on Wednesday, November 12, 2025 -- CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new [...]
Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics
30/10/2025
Reports Q3 revenue of $993.7 million, up 43.5% year-over-year Beats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit and adjusted EBITDA [...]
Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development
30/10/2025
New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today [...]
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
30/10/2025
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered [...]

Pages